Ukr.Biochem.J. 2022; Том 94, № 2, березень-квітень, c. 38-44

doi: https://doi.org/10.15407/ubj94.02.038

Рівні пухлинних біомаркерів CEA, CA19.9, CA15.3 та AFP у сироватці крові пацієнтів із COVID-19

18.07.2022   Uncategorized   No comments

Abubaker H. Ali1*, Abdullah H. Yaqub2, Ihssin A. Faraj2

1Department of Biotechnology, Faculty of Science, Sebha University, Libya;
2Department of Zoology, Faculty of Science, Sebha University, Libya;
*e-mail: Abu.Ali@sebhau.edu.ly

Отримано: 11 грудня 2021; Затверджено: 01 липня 2022

Рання діагностика дуже важлива для зниження рівня захворюваності і смертності у пацієнтів, інфікованих COVID-19. Метою даного дослідження було виявити пухлинні антигени CEA, CA19.9, CA15.3 та AFP та порівняти рівні цих антигенів у сироватці крові пацієнтів хворих на COVID-19 та здорових людей, які не хворіли на COVID-19. У дослідження було залучено 69 пацієнтів з COVID-19 і 69 здорових людей. Рівень СЕА, СА19.9, СА15.3 та AFP у сироватці крові визначали за допомогою ELISA. Встановлено, що рівень пухлинних біомаркерів у сироватці крові пацієнтів із Covid-19 складав 7,74 ± 4,65 нг/мл для CEA; 29,33 ± 16,35 од/мл для CA19.9; 23,24 ± 13,48 од/мл для CA15,3 та 7,46 ± 5,57 нг/мл для AFP, у той час, як рівень біомаркерів у сироватці крові осіб, які не хворіли на COVID-19 був 9,73 ± 43,58 нг/мл для CEA; 20,66 ± 11,10 од/мл для CA19.9; 19,64 ± 10,99 од/мл для CA15.3 та 3,83 ± 9,20 нг/мл для AFP. Таким чином, показано відсутність відмінностей у рівнях пухлинних біомаркерів двох досліджуваних груп. Зроблено висновок, що пухлинні біомаркери CEA, CA19.9, CA15.3 та AFP не можуть бути використані як ефективні інструменти скринінгу пацієнтів на COVID-19.

Ключові слова: , , , , ,

Посилання:

  1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207. PubMed, PubMedCentral, CrossRef
  2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. PubMed, PubMedCentral, CrossRef
  3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiri M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. PubMed, PubMedCentral, CrossRef
  4. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect. 2020;9(1):747-756. PubMed, PubMedCentral, CrossRef
  5. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J Clin Microbiol. 2020;58(6):e00512-20. PubMed, PubMedCentral, CrossRef
  6. World Health Organization. (2020). Laboratory testing for coronavirus disease 2019 (COVID-19) insuspected human cases: interim guidance, 2 March 2020.
  7. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. PubMed, PubMedCentral, CrossRef
  8. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-544. PubMed, PubMedCentral, CrossRef
  9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, M J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. PubMed, PubMedCentral, CrossRef
  10. Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr. 2021;8:607647. PubMed, PubMedCentral, CrossRef
  11. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, Gu Z, Gao L, Shi H, Mai L, Liu Y, Lin X, Lai R, Yan Z, Li X, Shan H. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020;69(6):997-1001. PubMed, PubMedCentral, CrossRef
  12. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liangv, Peng YX, Wei L, Liuv, Huv, Pengv, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. PubMed, PubMedCentral, CrossRef
  13. Purut YE, Giray B, Gurbuz E. Effect of the coronavirus pandemic on tumor markers. J Med Virol. 2021;93(9):5405-5408. PubMed, PubMedCentral, CrossRef
  14. Zhang L, Guo H. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv Biomark Sci Technol. 2020;2:1-23. PubMed, PubMedCentral, CrossRef
  15. Chen Q, Kong H, Qi X, Ding W, Ji N, Wu C, Huang C, Wu W, Huang M, Xie W, Liu Y, Tang J. Carcinoembryonic Antigen: A Potential Biomarker to Evaluate the Severity and Prognosis of COVID-19. Front Med (Lausanne). 2020;7:579543. PubMed, PubMedCentral, CrossRef
  16. Yu J, Yang Z, Zhou X, Wu D, Chen J, Zhang L, Tong L, Nie L. Prognostic value of carcinoembryonic antigen on outcome in patients with coronavirus disease 2019. J Infect. 2020;81(2):e170-e172. PubMed, PubMedCentral, CrossRef
  17. Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H. Elevations of serum cancer biomarkers correlate with severity of COVID-19. J Med Virol. 2020;92(10):2036-2041. PubMed, PubMedCentral, CrossRef
  18. Stockley RA, Shaw J, Whitfield AG, Whitehead TP, Clarke CA, Burnett D. Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions. Thorax. 1986;41(1):17-24. PubMed, PubMedCentral, CrossRef
  19. Hirakata Y, Kobayashi J, Sugama Y, Kitamura S. Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur Respir J. 1995;8(5):689-696.
    PubMed
  20. Barouchos N, Papazafiropoulou A, Iacovidou N, Vrachnis N, Barouchos N, Armeniakou E, Dionyssopoulo V, Mathioudakis AG, Christopoulou E, Koltsida S, Bassiakou E. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations. Scand J Clin Lab Invest. 2015;75(2):126-132. PubMed, CrossRef
  21. Klee GG, Go VLW. Carcinoembryonic antigen and its role in clinical practice. In Ghosh BC, Ghosh L eds.:Tumor markers and tumor-associated antigens: 1 st edition. NewYork: McGraw-Hill Book Company 1990;22-43.
  22. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122(3):467-481. PubMed, PubMedCentral, CrossRef
  23. Malati T. Tumour markers: An overview. Indian J Clin Biochem. 2007;22(2):17-31. PubMed, PubMedCentral, CrossRef
  24. Urban D, Catane R. Serum tumor markers in oncology. Isr Med Assoc J. 2009;11(2):103-104. PubMed
  25. Bonfrer JMG, Louhimo L. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Gastric Cancer, http://www.aacc.org/SiteCollectionDocuments/NACB/LMPG/tumor/chp3g_gastric.pdf.
  26. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68(6):1075-1082. PubMed
  27. Scientific Committee of the Association of Clinical Biochemists in Ireland (ACBI) Guidelines for the Use of Tumour Markers,
    http://www.acbi.ie/Downloads/Guidelines-for-the-Use-of-Tumour-Markers-2005.pdf. accessedJuni 15, 2011.
  28. Bédos JP, Hignette C, Lucet JC, Kilani B, Casalino E, Wolff M, Matheron S, Leport C, Vachon F. Serum carcinoembryonic antigen: a prognostic marker in HIV-related Pneumocystis carinii pneumonia. Scand J Infect Dis. 1992;24(3):309-315. PubMed, CrossRef
  29. Incoronato M, Mirabelli P, Catalano O, Aiello M, Parente C, Soricelli A, Nicolai E. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. BMC Cancer. 2014;14:356. PubMed, PubMedCentral, CrossRef
  30. Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, Prytomanova OM, Jacobs IJ, Widschwendter M, Menon U, Timms JF. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer. 2017;116(4):501-508. PubMed, PubMedCentral, CrossRef
  31. Wu JT, Nakamura RM, Clinton RS, Beason LK. A comparative study of four serological tumor markers for the detection of breast cancer. In: Wu JT, editor. Human circulating tumor markers: current concepts and clinical applications. Chicago: ASCP Press. 1997. p. 263.
  32. Scientific Committee of the Association of Clinical Biochemists in Ireland (ACBI) Guidelines for the Use of Tumour Markers, http://www.acbi.ie/Downloads/Guidelines-for-the-Use-of-Tumour-Markers-2005.pdf. accessed Juni 15, 2011.
  33. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138(9):951-956. PubMed, CrossRef
  34. Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214-2229. PubMed, CrossRef
  35. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, DienstagJL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG, Gretch DR. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43(3):434-441. PubMed, CrossRef
  36. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess Deaths From COVID-19 and Other Causes, March-April 2020. JAMA. 2020;324(5):510-513. PubMed, PubMedCentral, CrossRef
  37. Magnani C, Azzolina D, Gallo E, Ferrante D, Gregori D. How Large Was the Mortality Increase Directly and Indirectly Caused by the COVID-19 Epidemic? An Analysis on All-Causes Mortality Data in Italy. Int J Environ Res Public Health. 2020;17(10):3452. PubMed, PubMedCentral, CrossRef
  38. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33. PubMed, PubMedCentral, CrossRef
  39. Savarimuthu S, BinSaeid J, Harky A. The role of ECMO in COVID-19: Can it provide rescue therapy in those who are critically ill? J Card Surg. 2020;35(6):1298-1301. PubMed, PubMedCentral, CrossRef
  40. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Guo GY, Du J, Zheng CL, Zhu Q, Hu M, Li XY, Peng P, Shi HZ. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524. PubMed, PubMedCentral, CrossRef
  41. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. PubMed, PubMedCentral, CrossRef
  42. Lingaiah A, Srinivasarao Bandaru VCS. Role of Biomarker in COVID-19: A Study from Tertiary Care Center. Ann Infect Dis Epidemiol. 2021;6(1):1062.
  43. He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X. Tumor biomarkers predict clinical outcome of COVID-19 patients. J Infect. 2020;81(3):452-482. PubMed, PubMedCentral, CrossRef
  44. Ali AH. Serum Total and Free Prostate Specific Antigen Levels as Novel Biomarker in Patients with COVID-19. Iraq Med J. 2021;5(3):81-84. CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.